Literature DB >> 18828766

Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance.

Z Koporc1, N Pilat, P Nierlich, P Blaha, S Bigenzahn, I Pree, E Selzer, M Sykes, F Muehlbacher, T Wekerle.   

Abstract

Allogeneic bone marrow transplantation (BMT) under costimulation blockade allows induction of mixed chimerism and tolerance without global T-cell depletion (TCD). The mildest such protocols without recipient cytoreduction, however, require clinically impracticable bone marrow (BM) doses. The successful use of mobilized peripheral blood stem cells (PBSC) instead of BM in such regimens would provide a substantial advance, allowing transplantation of higher doses of hematopoietic donor cells. We thus transplanted fully allogeneic murine granulocyte colony-stimulating factor (G-CSF) mobilized PBSC under costimulation blockade (anti-CD40L and CTLA4Ig). Unexpectedly, PBSC did not engraft, even when very high cell doses together with nonmyeloablative total body irradiation (TBI) were used. We show that, paradoxically, T cells contained in the donor PBSC triggered rejection of the transplanted donor cells. Rejection of donor BM was also triggered by the cotransplantation of unmanipulated donor T cells isolated from naïve (nonmobilized) donors. Donor-specific transfusion and transient immunosuppression prevented PBSC-triggered rejection and mixed chimerism and tolerance were achieved, but graft-versus-host disease (GVHD) occurred. The combination of in vivo TCD with costimulation blockade prevented rejection and GVHD. Thus, if allogeneic PBSC are transplanted instead of BM, costimulation blockade alone does not induce chimerism and tolerance without unacceptable GVHD-toxicity, and the addition of TCD is required for success.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18828766      PMCID: PMC2992943          DOI: 10.1111/j.1600-6143.2008.02371.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  48 in total

Review 1.  Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?

Authors:  M Körbling; P Anderlini
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

2.  Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.

Authors:  A B Adams; M M Durham; L Kean; N Shirasugi; J Ha; M A Williams; P A Rees; M C Cheung; S Mittelstaedt; A W Bingaman; D R Archer; T C Pearson; E K Waller; C P Larsen
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

3.  Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice.

Authors:  P J Quesenberry; S Zhong; H Wang; M Stewart
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

Review 4.  Peripheral blood stem cells for allogeneic transplantation: a review.

Authors:  C Cutler; J H Antin
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

5.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.

Authors:  T Wekerle; J Kurtz; H Ito; J V Ronquillo; V Dong; G Zhao; J Shaffer; M H Sayegh; M Sykes
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

6.  The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo.

Authors:  K Kishimoto; V M Dong; S Issazadeh; E V Fedoseyeva; A M Waaga; A Yamada; M Sho; G Benichou; H Auchincloss; M J Grusby; S J Khoury; M H Sayegh
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

7.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.

Authors:  M Arpinati; C L Green; S Heimfeld; J E Heuser; C Anasetti
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

8.  Mixed chimerism and tolerance without whole body irradiation in a large animal model.

Authors:  Y Fuchimoto; C A Huang; K Yamada; A Shimizu; H Kitamura; R B Colvin; V Ferrara; M C Murphy; M Sykes; M White-Scharf; D M Neville; D H Sachs
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.

Authors:  M M Durham; A W Bingaman; A B Adams; J Ha; S Y Waitze; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

10.  Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L.

Authors:  Yasuo Takeuchi; Hiroshi Ito; Josef Kurtz; Thomas Wekerle; Leon Ho; Megan Sykes
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

View more
  5 in total

Review 1.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 2.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 3.  Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks.

Authors:  B Mahr; T Wekerle
Journal:  Clin Exp Immunol       Date:  2017-05-22       Impact factor: 4.330

4.  Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy.

Authors:  Ulrike Baranyi; Andreas M Farkas; Karin Hock; Benedikt Mahr; Birgit Linhart; Martina Gattringer; Margit Focke-Tejkl; Arnd Petersen; Fritz Wrba; Thomas Rülicke; Rudolf Valenta; Thomas Wekerle
Journal:  EBioMedicine       Date:  2016-03-20       Impact factor: 8.143

Review 5.  Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation.

Authors:  Benedikt Mahr; Nicolas Granofszky; Moritz Muckenhuber; Thomas Wekerle
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.